February 19, 2014 12:00 PM
Lectures and Panels
Wasserstein Hall 1015
1585 Massachusetts Ave., Cambridge, MA

In the pharmaceutical industry, patents are the preeminent incentive for innovation in developing new drugs.  But patents aren’t the whole story; regulatory agencies also offer different forms of exclusivity—enforced by the agencies themselves—to encourage different forms of innovation in the industry.  This panel discussed actual and potential roles for those rewards in the context of developing new drugs, new uses for old drugs, and new ways to make drugs, in both the United States and the European Union. Panelists were:

  • Benjamin N. Roin, Hieken Assistant Professor in Patent Law, Harvard Law School; Faculty Co-Director, the Petrie-Flom Center

  • W. Nicholson Price II, Academic Fellow, the Petrie-Flom Center

  • Timo Minssen, Associate Professor, University of Copenhagen Faculty of Law; Visiting Scholar, the Petrie-Flom Center

  • Moderator, Aaron Kesselheim, Assistant Professor of Medicine, Harvard Medical School; Director of the Program On Regulation, Therapeutics, And Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital

For questions, contact petrie-flom@law.harvard.edu or 617-495-2316.

Video of this event is now available online:

You can also download the slides used during individual presentations:

Watch the full event online.


benjamin n. roin   health law policy   innovation   intellectual property   international   pharmaceuticals   regulation   w. nicholson price ii